Business Description
Lytix Biopharma AS
ISIN : NO0010405780
Share Class Description:
FRA:6BG: Ordinary SharesTotal Employee Number:
14Description
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 51.72 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.7 | |||||
3-Year EPS without NRI Growth Rate | 14.5 | |||||
3-Year FCF Growth Rate | 13 | |||||
3-Year Book Growth Rate | -35.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -28.59 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.77 | |||||
9-Day RSI | 58.58 | |||||
14-Day RSI | 53.46 | |||||
3-1 Month Momentum % | -17.04 | |||||
6-1 Month Momentum % | -8.64 | |||||
12-1 Month Momentum % | 13.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.6 | |||||
Quick Ratio | 7.6 | |||||
Cash Ratio | 7.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.4 | |||||
Shareholder Yield % | -11.94 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -109.69 | |||||
ROA % | -91.64 | |||||
ROIC % | -845.06 | |||||
3-Year ROIIC % | 33.3 | |||||
ROC (Joel Greenblatt) % | -4564.98 | |||||
ROCE % | -110.09 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.46 | |||||
Price-to-Tangible-Book | 7.44 | |||||
EV-to-EBIT | -5.54 | |||||
EV-to-EBITDA | -5.6 | |||||
EV-to-FCF | -6.39 | |||||
Price-to-GF-Value | 37.2 | |||||
| Price-to-Net-Current-Asset-Value | 7.44 | |||||
| Price-to-Net-Cash | 8.27 | |||||
Earnings Yield (Greenblatt) % | -18.05 | |||||
FCF Yield % | -13.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lytix Biopharma AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.114 | ||
| Beta | -1.0711 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.81 | ||
| Volatility % | 49.01 | ||
| 14-Day RSI | 53.46 | ||
| 14-Day ATR (€) | 0.016184 | ||
| 20-Day SMA (€) | 0.706 | ||
| 12-1 Month Momentum % | 13.7 | ||
| 52-Week Range (€) | 0.566964 - 1.015 | ||
| Shares Outstanding (Mil) | 76.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lytix Biopharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lytix Biopharma AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-12 10:00 | In 161 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 160 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-11 | In 67 days | ||
| Third quarter earnings results for 2026 | 2026-11-11 | In 67 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-27 14:00 | 0.68 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-27 | 0.68 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-21 14:00 | 0.92 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-21 | 0.92 (+0.00%) | ||
| General meeting for 2026 | 2026-04-14 13:00 | 0.91 (+0.00%) | ||
| Annual report for 2025 | 2026-03-24 | 0.92 (+0.00%) |
Show
Entries
Lytix Biopharma AS Frequently Asked Questions
What is Lytix Biopharma AS(FRA:6BG)'s stock price today?
The current price of FRA:6BG is €0.74. The 52 week high of FRA:6BG is €1.01 and 52 week low is €0.57.
When is next earnings date of Lytix Biopharma AS(FRA:6BG)?
The next earnings date of Lytix Biopharma AS(FRA:6BG) is 2026-11-11.
Does Lytix Biopharma AS(FRA:6BG) pay dividends? If so, how much?
Lytix Biopharma AS(FRA:6BG) does not pay dividend.
Press Release
Articles on Lytix Biopharma AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers